How to Get Payment Processing for a Lawful RUO Peptide Business

Establish which business is actually seeking processing

Write a short description identifying the selling entity, products, intended customers, operating country and delivery destinations. Distinguish laboratory supply from cosmetic retail, clinical care and prescription fulfillment. Those models should not be treated as interchangeable simply because each involves peptides.

FDA's February 2025 USApeptide.com warning letter illustrates why the distinction matters: FDA found evidence of intended human use despite research disclaimers. That finding concerned the seller and products identified in the letter, not every laboratory supplier. It shows why the underlying activity must be resolved rather than concealed. FDA: USApeptide.com warning letter, February 26, 2025

• Create an accurate catalog by substance, formulation, package size, supplier and intended research application.
• Explain who may buy and how orders inconsistent with the research model are handled.
• Identify any separate clinical, cosmetic or consumer-facing activity and disclose the relevant entities and websites.
• Pause products or practices whose lawful status is unresolved; do not keep selling them under a different description.

Separate certification, product testing and buyer qualification

There is no single website credential that makes every RUO seller eligible. LegitScript's healthcare certification FAQ currently places research-use-only chemical businesses, including peptides, among businesses generally outside that program's scope, while recognizing that additional in-scope healthcare activities can change the assessment. Confirm eligibility directly before buying a certification service. LegitScript: Healthcare certification eligibility FAQ

Ask a prospective partner precisely which evidence it requires, from whom and for which activity. Do not advertise FDA approval, medical suitability or healthcare certification unless it is accurate and applicable. A certificate of analysis should be traceable to the supplied lot and understood within the tests performed, not promoted as a universal safety certificate.

Review the entire sales journey, not just the product disclaimer

Audit product pages, advertising, affiliate landing pages, emails and customer-support scripts against the actual research business. Human dosing advice, treatment promises or personal-use promotion can contradict a research-only proposition. If that is how the business operates, changing a few phrases is not a remedy. Escalate the underlying issue and disclose material concerns.

LegitScript's processor guide highlights buyer safeguards and the wider presentation of research products as review considerations. Treat this as a risk-review perspective, not a universal legal checklist. Document the buyer-screening process appropriate to your business and ask the proposed partner what controls it expects. LegitScript: Understanding peptides: processor and platform guide

• Show who sells the goods, how support can be reached and which destinations are actually served.
• State accurate product descriptions, prices, order conditions and realistic delivery times.
• Explain eligibility checks before the customer commits, including how unsuitable orders are declined or refunded.
• Keep supplier, lot and dispatch records connected so an order can be investigated without guesswork.
• Apply the same standards to affiliates; a restrained storefront does not cancel misleading promotion elsewhere.

Prepare a concise application file and distinguish forecasts from history

Start with the legal entity, ownership summary, website, business banking arrangement, catalog and fulfillment model. Existing sellers should reconcile processing history to actual orders, refunds and disputes. New sellers should state plainly that they have no history and explain inventory, working capital and a supportable launch forecast.

Public specialist materials show variation rather than a universal program. AllayPay lists banking, processing and inventory or supplier evidence on its peptide page; PeptidePay Canada describes entity, website and fulfillment readiness for its Canadian program. Those are their published practices, not MerchantBridge partner requirements, pricing or confirmed availability. AllayPay: Published peptide merchant program informationPeptidePay Canada: Published merchant readiness guidance

• Use actual settled volume, order count, typical ticket and largest expected transaction for a consistent period.
• Separate current stock from goods not yet available and explain who controls fulfillment.
• Describe previous account decisions accurately, including unresolved issues and corrective work.
• Keep supporting records ready for a requested private handoff; do not send IDs, bank records or customer information through the initial contact message.

Confirm category acceptance before paying for an integration

Ask whether the proposed acquiring arrangement can review the actual entity, countries and full catalog. Then confirm compatibility among the merchant account, gateway, shopping platform and recurring-payment requirements. A plugin listing or successful test payment is not approval for the business category.

Request the complete written proposal: transaction and gateway charges, minimums, any reserve, funding timing, volume conditions, termination terms and responsibilities for ongoing review. Compare those against cash needed for inventory and delivery. Do not import another provider's advertised reserve or turnaround time into your own forecast.

ACH or international acquiring may be worth discussing for an eligible business, but neither is a workaround for unlawful sales or an undisclosed category. MerchantBridge can explore potential relationships, including domestic and international channels, without promising that a particular catalog or jurisdiction will be accepted.

Launch only within the reviewed operating scope

• Confirm the approved entity, domains, catalog and transaction configuration in writing.
• Test the permitted checkout, receipt, refund and failed-payment paths with the provider's test tools.
• Reconcile the first permitted live transactions to orders and provider reports; do not generate fabricated sales.
• Assign an owner to complaints, product changes and requested periodic reviews.
• Discuss material changes before adding a new sales model, destination, product line or sharp volume increase.

The operating file should remain understandable after onboarding. Keep a dated record of what changed and what the partner confirmed. A previously accepted product or account does not establish permission for a different use or a new entity.

For ISOs: evaluate a research supplier before making the introduction

An inquiry outside your current sponsor's appetite is not automatically a dead lead. First distinguish a category restriction from an unresolved legality, disclosure or operating problem. MBA may be able to explore another acquiring relationship for a properly described lawful business; it cannot make prohibited activity acceptable.

Ask for the merchant's permission to discuss the opportunity. Establish the legal entity, research customer base, full catalog, destinations and payment need. Record whether the merchant is pre-launch, established or planning a change. If the current program requires a credential that does not apply to the model, clarify that discrepancy rather than presenting an irrelevant certificate as a solution.

Agree who will communicate with the merchant and what may be shared before an introduction. Referral compensation, residual arrangements, support obligations and any relationship protections require a specific agreement. A potential introduction is not a promise of exclusivity, white-label service, approval or a particular buy rate.

Bring MBA a specific RUO placement question

• Your ISO or agency name and your own business contact details.
• The merchant's research model, entity country and intended destinations, with permission to share identifying information.
• Approximate volume and tickets, clearly marked actual or forecast, plus the platform and methods required.
• The reason existing relationships cannot consider the case, and any compliance questions still open.
• Whether you want an initial category discussion or a coordinated merchant introduction.

A useful opening is: 'We have a research supplier inquiry our current program does not cover. Can we discuss the disclosed catalog, customer controls and geography before requesting a full application?' Keep customer lists, raw financial records and sensitive product documentation out of that first message. MBA can establish what a potential next-stage review needs.